Hemak, president and CEO of the Wright Centers for Community Health and Graduate Medical Education, was named one of the 100 most powerful and influential female leaders in ...
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Time-restricted eating (TRE) may not add additional benefit in visceral adipose tissue reduction over the Mediterranean diet ...
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...
GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...
A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...
The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
California gastroenterologist Dr. Saurabh Sethi has called out three popular drinks that increase the risk of Alzheimer’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback